GTC Biotherapeutics (fka GTCB)

[quantumdot]

re GTC's strong data. you are both using the term "strong data" to defend your views on the likelihood of an advisory panel for ATryn. My only caution is that although the data points they have are good (safety, equivalence etc.,) they are very few in number. I know this is in a very small patient population and larger trials were not commercially feasible.

However, IMO, it is precisely because it is a new technology and because the number of data points is so few that the FDA may ask for an advisory panel. If this happens, I agree with Dew that it would not be good as it will inevitably provide a forum for a discussion of the social acceptance of transgenic pharmaceuticals. Exactly what GTC does not need!